Hospital
Columbus Community Hospital INC
Columbus Community Hospital INC was paid $8.91M by Medicaid between Jan 2018 and Nov 2024, across 97 billing codes. Its largest line is 92507, Treatment of speech, language, voice, communication, and/or auditory processing disorder — 27% of everything it billed.
33Billing provider infoCOLUMBUS COMMUNITY HOSPITAL INC
COLUMBUS, NE 68601
COLUMBUS, NE 68601
33aNPI1760589295assigned 09/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.91M
24GClaims153,760
24DCodes billed97
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nebraska
Rank by total paid#2 of 8
Median peer was paid$1.62M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,827 | $904K | |
| 2019 | 21,792 | $931K | |
| 2020 | 19,409 | $1.24M | |
| 2021 | 32,773 | $1.85M | |
| 2022 | 32,927 | $1.78M | |
| 2023 | 17,109 | $1.27M | |
| 2024incomplete | 7,923 | $933K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 27% | 20,335 | 6,331 | $2.37M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 17% | 20,704 | 5,599 | $1.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 7,529 | 6,932 | $1.32M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 15,772 | 4,485 | $1.17M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 2,895 | 2,760 | $455K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.2% | 2,293 | 2,116 | $372K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 780 | 622 | $272K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 1,649 | 1,562 | $184K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 423 | 394 | $132K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 2,717 | 1,048 | $122K |
| 80050 | General health panel | 1.3% | 7,909 | 4,113 | $114K |
| 97116 | 1.3% | 2,240 | 984 | $114K |
85 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 476 | $66K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,035 | $56K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 191 | $55K |
| 97161 | <1% | 515 | $54K | |
| J3490 | Unclassified drugs | <1% | 6,666 | $51K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 610 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 551 | $42K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 215 | $37K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,524 | $34K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,786 | $33K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 728 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,660 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 655 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,314 | $17K |
| G0378 | Hospital observation service, per hour | <1% | 73 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,027 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,577 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,138 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 126 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 409 | $8K |
| 99285 | Emergency room visit (most serious) | <1% | 73 | $8K |
| 86140 | <1% | 3,190 | $7K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,676 | $7K |
| 97165 | <1% | 56 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,854 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,723 | $6K |
| 81001 | <1% | 3,479 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,541 | $5K |
| 74018 | <1% | 72 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,699 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,013 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 40 | $4K |
| 92523 | <1% | 40 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,787 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 31 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 362 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 304 | $3K |
| 83690 | <1% | 1,676 | $3K | |
| 82150 | <1% | 1,301 | $3K | |
| 83735 | <1% | 1,201 | $3K | |
| 97597 | <1% | 21 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 875 | $3K |
| 84439 | <1% | 221 | $2K | |
| 97164 | <1% | 14 | $2K | |
| 87430 | <1% | 142 | $2K | |
| 85027 | <1% | 774 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 437 | $2K |
| 94664 | <1% | 116 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 285 | $2K |
| 87081 | <1% | 132 | $2K | |
| 84484 | <1% | 820 | $1K | |
| 85610 | <1% | 1,151 | $1K | |
| 87634 | <1% | 69 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $1K |
| 87186 | <1% | 584 | $1K | |
| S9152 | Speech therapy, re-evaluation | <1% | 15 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 157 | $820.24 |
| 84703 | <1% | 377 | $657.90 | |
| 87088 | <1% | 312 | $528.67 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 40 | $494.30 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 118 | $473.58 |
| 87040 | <1% | 108 | $445.75 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 545 | $442.26 |
| 87486 | <1% | 216 | $370.10 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 43 | $346.88 |
| 80061 | Lipid panel | <1% | 55 | $302.87 |
| 80306 | <1% | 182 | $222.62 | |
| 87581 | <1% | 216 | $217.73 | |
| 82728 | <1% | 16 | $200.00 | |
| 84145 | <1% | 48 | $186.80 | |
| 83605 | <1% | 167 | $185.44 | |
| 85652 | <1% | 27 | $135.10 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12 | $104.45 |
| 85379 | <1% | 69 | $90.00 | |
| 83540 | <1% | 14 | $88.90 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 242 | $45.81 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 135 | $39.80 |
| 85730 | <1% | 101 | $13.55 | |
| 81025 | <1% | 12 | $3.02 | |
| 82077 | 0% | 107 | $0.00 | |
| 94761 | 0% | 20 | $0.00 | |
| 96376 | 0% | 21 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 55 | $0.00 |
| 94760 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVAN CLEAVE, CHAD (VICE-PRESIDENT FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Columbus Community Hospital INC | Columbus, NE | $677K |
| Columbus Community Hospital INC | Columbus, NE | $398K |
| Columbus Community Hospital INC | Columbus, NE | $14K |
| Columbus Community Hospital INC | Columbus, NE | $13K |
| Columbus Community Hospital INC | Columbus, NE | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.